CharlesHooshmandNightingaleMD

PubMed

• 1 citations
  Pharmacodynamic profiling of modithromycin: assessment in a pneumococcal murine pneumonia model.
  Dana Maglio, Heather K. Sun, Toral Patel, Mary Anne Banevicius, Charles H. Nightingale, Anu Arya, Guoqiang Wang, Zhigang Chen, Ly T. Phan, David P. Nicolau> ;International Journal of Antimicrobial Agents. 2014 Jun 1
• 47 citations
  Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
  Christine T. Ong, Pamela R. Tessier, Chonghua Li, Charles H. Nightingale, David P. Nicolau> ;Diagnostic Microbiology and Infectious Disease. 2007 Feb 1
• 109 citations
  Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study.
  Su Young Lee, Srividya Kotapati, Joseph L. Kuti, Charles H. Nightingale, David P. Nicolau> ;Infection Control and Hospital Epidemiology. 2006 Oct 23
• 128 citations
  Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients
  Chonghua Li, Joseph L. Kuti, Charles H. Nightingale, David P. Nicolau> ;Journal of Clinical Pharmacology. 2006 Oct 1
• 47 citations
  Tissue Penetration of Telavancin after Intravenous Administration in Healthy Subjects
  Heather K. Sun, Kenneth Duchin, Charles H. Nightingale, Jeng-Pyng Shaw, Julie D. Seroogy, David P. Nicolau> ;Antimicrobial Agents and Chemotherapy. 2006 Feb 1
• 40 citations
  Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients.
  Xiaoli Du, Chonghua Li, Joseph L. Kuti, Charles H. Nightingale, David P. Nicolau> ;Journal of Clinical Pharmacology. 2006 Jan 1
• 9 citations
  Future in vitro and animal studies: development of pharmacokinetic and pharmacodynamic efficacy predictors for tissue-based antibiotics.
  Charles H. Nightingale> ;Pharmacotherapy. 2005 Dec 1
• 27 citations
  Clinical implications of extended spectrum β-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness
  Srividya Kotapati, Joseph L. Kuti, Charles H. Nightingale, David P. Nicolau> ;The Journal of Infection. 2005 Oct 1
• Evaluation of telithromycin against Streptococcus pneumoniae with ribosomal mutations utilizing in vitro time-kill methodology.
  Prachi K. Dandekar, Pamela R. Tessier, David J. Farrell, Charles H. Nightingale, David P. Nicolau> ;International Journal of Antimicrobial Agents. 2005 Oct 1
• 26 citations
  A sensitive assay of amoxicillin in mouse serum and broncho-alveolar lavage fluid by liquid-liquid extraction and reversed-phase HPLC.
  Xiaoli Du, Chonghua Li, Heather K. Sun, Charles H. Nightingale, David P. Nicolau> ;Journal of Pharmaceutical and Biomedical Analysis. 2005 Sep 15
• 39 citations
  Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs)
  Christine T. Ong, Chinedum P. Babalola, Charles H. Nightingale, David P. Nicolau> ;The Journal of Antimicrobial Chemotherapy. 2005 Sep 1
• 80 citations
  Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
  Chonghua Li, Joseph L. Kuti, Charles H. Nightingale, Debra Mansfield, Adrian Dana, David P. Nicolau> ;The Journal of Antimicrobial Chemotherapy. 2005 Aug 1
• 21 citations
  Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem.
  Joseph L. Kuti, Sheryl Horowitz, Charles H. Nightingale, David P. Nicolau> ;Pharmacotherapy. 2005 Jul 1
• 5 citations
  Assessment of the efficacy of telithromycin simulating human exposures against S. pneumoniae with ribosomal mutations in a murine pneumonia model
  Prachi K. Dandekar, Peter Williams, Pamela R. Tessier, David J. Farrell, Charles H. Nightingale, David P. Nicolau> ;International Journal of Antimicrobial Agents. 2005 Jun 1
• 10 citations
  The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion.
  Srividya Kotapati, Joseph L. Kuti, Erika C. Geissler, Charles H. Nightingale, David P. Nicolau> ;Intensive & Critical Care Nursing. 2005 Apr 1
• 68 citations
  Pharmacokinetic Profile of Tigecycline in Serum and Skin Blister Fluid of Healthy Subjects after Multiple Intravenous Administrations
  Heather K. Sun, Christine T. Ong, Ambreen Umer, Dawn Harper, Steven Troy, Charles H. Nightingale, David P. Nicolau> ;Antimicrobial Agents and Chemotherapy. 2005 Apr 1
• 15 citations
  A survey of the quality of generic clarithromycin products from 18 countries.
  Charles H. Nightingale> ;Clinical Drug Investigation. 2005 Jan 1
• 8 citations
  Simultaneous analysis of piperacillin and tazobactam in rabbits: application to pharmacokinetic study.
  Chonghua Li, Dawei Xuan, Ming Ye, Charles H. Nightingale, David P. Nicolau> ;Biomedical Chromatography. 2005 Jan 1
• 20 citations
  Pharmacodynamic Profile of Ertapenem against Klebsiella pneumoniae and Escherichia coli in a Murine Thigh Model
  Dana Maglio, Mary Anne Banevicius, Christina A. Sutherland, Chinedum P. Babalola, Charles H. Nightingale, David P. Nicolau> ;Antimicrobial Agents and Chemotherapy. 2005 Jan 1
• 20 citations
  Pharmacodynamic Profile of Telithromycin against Macrolide- and Fluoroquinolone-Resistant Streptococcus pneumoniae in a Neutropenic Mouse Thigh Model
  Pamela R. Tessier, Holly M. Mattoes, Prachi K. Dandekar, Charles H. Nightingale, David P. Nicolau> ;Antimicrobial Agents and Chemotherapy. 2005 Jan 1
• 27 citations
  Quantitation of tigecycline, a novel glycyclcycline, by liquid chromatography
  Chonghua Li, Christina A. Sutherland, Charles H. Nightingale, David P. Nicolau> ;Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 2004 Nov 25
• 2 citations
  Effect of adjunctive treatment with gamma interferon against Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts.
  Chinedum P. Babalola, Charles H. Nightingale, David P. Nicolau> ;International Journal of Antimicrobial Agents. 2004 Sep 1
• 84 citations
  Optimizing Pharmacodynamic Target Attainment Using the MYSTIC Antibiogram: Data Collected in North America in 2002
  Joseph L. Kuti, Charles H. Nightingale, David P. Nicolau> ;Antimicrobial Agents and Chemotherapy. 2004 Jul 1
• 17 citations
  Differential efficacy of clarithromycin in lung versus thigh infection models.
  Dana Maglio, Blair Capitano, Mary Anne Banevicius, Qiuming Geng, Charles H. Nightingale, David P. Nicolau> ;Chemotherapy. 2004 Jun 1
• 29 citations
  Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts.
  Srividya Kotapati, David P. Nicolau, Charles H. Nightingale, Joseph L. Kuti> ;American Journal of Health-System Pharmacy. 2004 Jun 15
• Join now to see all